Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab and Tepotinib Combination in MET-altered NSCLC
NCT06083857Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab, tepotinib in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2024; status: active, not recruiting.
02
Drugs
amivantamabtepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06083857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083857.